Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04417621 · ClinicalTrials.gov registry record · Phase 2
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
A Phase 2 study of Melanoma, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 134
- Enrollment target
- 20
- Study locations
NCT04417621 is a Phase 2 study of Melanoma that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 134 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT04417621, a Phase 2 study of Melanoma, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 134 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to evaluate the efficacy of LXH254 combinations in previously treated unresectable or metastatic melanoma
Conditions Studied
Interventions
- DRUG Ribociclib
- DRUG Trametinib
- DRUG LXH254
- DRUG LTT462
Study Locations (20)
Other
- Novartis Investigative Site - Leuven
- Novartis Investigative Site - Wilrijk
- Novartis Investigative Site - Lille
- Novartis Investigative Site - Marseille
California
- The Angeles Clinic and Research Institute - Los Angeles
- UCSF Medical Center - San Francisco
Florida
- Florida Cancer Specialists - Fort Myers
- H Lee Moffitt Cancer Center and Research Institute - Tampa
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Minnesota
- Mayo Clinic Mayo Rochester - Rochester
- Mayo Clinic Rochester - Rochester
New York
- NYU Laura and Isaac Perlmutter Cancer Center - New York
- Memorial Sloan Kettering - New York
Pennsylvania
- University of Pittsburgh Med Center - Pittsburgh
Texas
- Univ of TX MD Anderson Cancer Cntr - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2020-10-30 |
| Est. Completion | 2027-02-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04417621
The ClinicalTrials.gov registry entry for NCT04417621 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (81% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 4 interventions - of which Ribociclib is the first listed.
NCT04417621 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT04417621 about?
NCT04417621 is a clinical study titled "Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma". The primary purpose of this study is to evaluate the efficacy of LXH254 combinations in previously treated unresectable or metastatic melanoma
What is the current status of trial NCT04417621?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 134 participants. The study started on 2020-10-30. Estimated completion is 2027-02-02.
What conditions does trial NCT04417621 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT04417621?
The interventions under investigation include: Ribociclib (DRUG), Trametinib (DRUG), LXH254 (DRUG), LTT462 (DRUG).
Who is sponsoring clinical trial NCT04417621?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04417621 being conducted?
This trial has 20 study locations across California, Florida, Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.